Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus.
Diabetes Res Clin Pract
; 149: 140-146, 2019 Mar.
Article
en En
| MEDLINE
| ID: mdl-30716347
ABSTRACT
AIMS:
Information on the clinical efficacy of SGLT2 inhibitors in the Japanese population is limited. The aim of this single-arm, single-center, open-label study was to confirm the body weight- and fat mass-lowering effects of canagliflozin (CANA) and the accompanying improvement in insulin resistance in Japanese patients with Type 2 diabetes mellitus (T2DM).METHODS:
Thirty-eight patients were enrolled and administered 100â¯mg CANA once daily for 24â¯weeks. Blood and anthropometric parameters were examined before and after treatment. In a subset of patients, insulin sensitivity was assessed based on the glucose infusion rate (GIR) during a hyperinsulinemic euglycemic clamp test.RESULTS:
CANA treatment significantly decreased hemoglobin A1c, fasting plasma glucose, and plasma liver enzyme levels, and increased plasma adiponectin levels. In addition, a significant reduction in body weight, visceral and subcutaneous fat area, fat and lean mass, and liver steatosis was also observed. The change in plasma adiponectin levels significantly correlated with the changes in both body fat mass and visceral fat area. GIR increased from 3.25⯱â¯1.53 to 4.11⯱â¯1.30â¯mg/kg/min (Pâ¯<â¯0.05).CONCLUSIONS:
CANA improved insulin resistance and decreased visceral fat mass in Japanese patients with T2DM.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Peso Corporal
/
Resistencia a la Insulina
/
Diabetes Mellitus Tipo 2
/
Canagliflozina
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
Límite:
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Asia
Idioma:
En
Año:
2019
Tipo del documento:
Article